AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) EV/FCF
As of 9 October 2026, AbbVie Inc. (ABBV) trades at a EV/FCF of 30.4×. Over the past ten years it has ranged from 9.6× (March 2020) to 39.0× (January 2015); the current reading is higher than 96% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 26.2× | 24.19% |
| FY2024 | 21.1× | 41.32% |
| FY2023 | 14.9× | 5.89% |
| FY2022 | 14.1× | 1.07% |
| FY2021 | 13.9× | (8.65%) |
| FY2020 | 15.3× | 23.40% |
| FY2019 | 12.4× | (9.28%) |
| FY2018 | 13.6× | (30.38%) |
| FY2017 | 19.6× | (2.41%) |
| FY2016 | 20.1× | 17.54% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 28.0× | 24.64% |
| Mar 2026 | 22.4× | (14.28%) |
| Dec 2025 | 26.2× | 9.04% |
| Sep 2025 | 24.0× | 11.67% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| GILD Gilead Sciences, Inc. compare | 16.3× |
| NVS Novartis AG compare | 20.6× |
| PFE Pfizer Inc. compare | 20.9× |
| MRK Merck & Co., Inc. compare | 25.1× |
| AMGN Amgen Inc. compare | 27.4× |
| JNJ Johnson & Johnson compare | 28.4× |
| ABBV AbbVie Inc. | 30.4× |
| AZN AstraZeneca PLC compare | 43.3× |
| LLY Eli Lilly and Company compare | 53.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement